| Thomas P Reis, O D PS | |
|
811 Georgiana St, Port Angeles, WA 98362-3511 | |
| (360) 417-2020 | |
| (360) 417-0254 |
| Full Name | Thomas P Reis |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 33 Years |
| Location | 811 Georgiana St, Port Angeles, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588776744 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2042 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Coast Eye Care Llc | 7012215684 | 2 |
News Archive
Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.
New research has supported the trends that regularly consuming a diet of fried food, meat, sugary drinks may increase the risk of sudden cardiac death.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.
› Verified 8 days ago
| Provider Name | North Coast Eye Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780041491 PECOS PAC ID: 7012215684 Enrollment ID: O20160414001232 |
News Archive
Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.
New research has supported the trends that regularly consuming a diet of fried food, meat, sugary drinks may increase the risk of sudden cardiac death.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas P Reis, O D PS 811 Georgiana St, Port Angeles, WA 98362-3511 Ph: (360) 417-2020 | Thomas P Reis, O D PS 811 Georgiana St, Port Angeles, WA 98362-3511 Ph: (360) 417-2020 |
News Archive
Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.
New research has supported the trends that regularly consuming a diet of fried food, meat, sugary drinks may increase the risk of sudden cardiac death.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.
› Verified 8 days ago
Dr. Kirk Thompson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 811 Georgiana St, Port Angeles, WA 98362 Phone: 360-452-7661 Fax: 360-417-0254 | |
Thomas O Mccurdy Od Inc Ps Optometrist Medicare: Medicare Enrolled Practice Location: 504 E 8th St Ste A, Port Angeles, WA 98362 Phone: 360-457-1032 Fax: 360-452-9604 | |
George B Symonds, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1122 E Front St, Port Angeles, WA 98362 Phone: 360-457-1161 Fax: 360-457-2806 | |
Steven D. Lewis, Od, Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 901 S Lincoln St, Port Angeles, WA 98362 Phone: 360-452-9060 Fax: 360-457-1686 | |
John P Huard, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1026 E 1st St Ste A, Port Angeles, WA 98362 Phone: 360-452-2020 Fax: 360-452-8087 | |
Dr. Lawrence William Nivala, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 114 E 1st St, Port Angeles, WA 98362 Phone: 360-452-2361 Fax: 360-452-2362 | |
Angeles Vision Clinic, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 811 Georgiana St, Port Angeles, WA 98362 Phone: 360-452-7661 Fax: 360-417-0254 |